A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumorsMATEO, J; BERLIN, J; BORGHAEI, H et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 1039-1046, issn 0344-5704, 8 p.Article

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancerYEE CHAO; HSIEH, Jan-Sing; LI, Chung-Pin et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 4, pp 799-806, issn 0344-5704, 8 p.Article

A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancerCHAN, S; CAMPONE, M; SANTORO, A et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 903-910, issn 0344-5704, 8 p.Article

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)SHOJI, Tadahiro; TAKATORI, Eriko; NISHIYAMA, Hiroshi et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 895-901, issn 0344-5704, 7 p.Article

A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesotheliomaARRIETA, Oscar; LOPEZ-MARIAS, Diego; MENDOZA-GARCIA, Víctor-Osvaldo et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 975-982, issn 0344-5704, 8 p.Article

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumorsMAISON-BLANCHE, Pierre; DAKHIL, Shaker; YACHNIN, Jeffrey et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 6, pp 1241-1252, issn 0344-5704, 12 p.Article

Antitumor effects of BI-D1870 on human oral squamous cell carcinomaCHIU, Chang-Fang; BAI, Li-Yuan; KAPURIYA, Naval et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 2, pp 237-247, issn 0344-5704, 11 p.Article

Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 levelANJING GONG; NA GE; WEICHENG YAO et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 3, pp 531-538, issn 0344-5704, 8 p.Article

Autophagy, a novel target for chemotherapeutic intervention of thyroid cancerLI, Le-Chen; LIU, Guo-Dong; ZHANG, Xin-Jie et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 439-449, issn 0344-5704, 11 p.Article

Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide productionLEI GONG; BO YANG; MING XU et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 1, pp 69-77, issn 0344-5704, 9 p.Article

Circulating proteins as potential biomarkers of sunitinib and interferon-a efficacy in treatment-naïve patients with metastatic renal cell carcinomaHARMON, Charles S; DEPRIMO, Samuel E; EISEN, Tim et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 1, pp 151-161, issn 0344-5704, 11 p.Article

Determining the mechanisms of lapatinib-induced diarrhoea using a rat modelBOWEN, Joanne M; MAYO, Bronwen J; PLEWS, Erin et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 3, pp 617-627, issn 0344-5704, 11 p.Article

DrugPath: a database for academic investigators to match oncology molecular targets with drugs in developmentSHAH, Eric D; FISCH, Brandon M. A; ARCECI, Robert J et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 1089-1093, issn 0344-5704, 5 p.Article

Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasmaYUNG, Raymond; SEYFODDIN, Vahid; GUISE, Christopher et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 639-649, issn 0344-5704, 11 p.Article

Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutationIGAWA, Satoshi; KASAJIMA, Masashi; KATONO, Ken et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 939-946, issn 0344-5704, 8 p.Article

Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjectsNARASIMHAN, Narayana I; DORER, David J; DAVIS, Jeffrey et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 341-348, issn 0344-5704, 8 p.Article

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trialBECERRA, Carlos R; SALAZAR, Ramon; GREEN, Stephanie et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 4, pp 695-702, issn 0344-5704, 8 p.Article

GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)POVEDA, Andrés; DEL MURO, Xavier García; LOPEZ-GUERRERO, Jose Antonio et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 883-898, issn 0344-5704, 16 p.Article

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studiesMACHIELS, Jean-Pascal; STADDON, Arthur; SHARMA, Sunil et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 4, pp 729-737, issn 0344-5704, 9 p.Article

Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignanciesAGGARWAL, Rahul; GRABOWSKY, Jennifer; STRAIT, Noah et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 359-365, issn 0344-5704, 7 p.Article

Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivoZHONGYI HU; DENGLU ZHANG; JIANRONG HAO et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 2, pp 397-407, issn 0344-5704, 11 p.Article

Mechanisms affecting neutrophil migration capacity in breast cancer patients before and after chemotherapyMENDONCA, Maria Angélica Oliveira; SOUTO, Fabrício O; MICHELI, Douglas C et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 2, pp 317-324, issn 0344-5704, 8 p.Article

Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugatesWADA, Russ; ERICKSON, Hans K; LEWIS PHILLIPS, Gail D et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 969-980, issn 0344-5704, 12 p.Article

Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993)REID, Joel M; BUHROW, Sarah A; GILBERT, Judith A et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 6, pp 1137-1146, issn 0344-5704, 10 p.Article

Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen studyAKGUN, Zuleyha; SAGLAM, Sezer; YUCEL, Serap et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 4, pp 751-756, issn 0344-5704, 6 p.Article